Takeda shareholder group aims to block $62 billion Shire deal

Image
Reuters TOKYO
Last Updated : Jun 11 2018 | 5:45 PM IST

By Sam Nussey

TOKYO (Reuters) - A group of Takeda Pharmaceutical Co Ltd shareholders is trying to build support to block the $62 billion acquisition of London-listed Shire Plc at an extraordinary general meeting, a leading member of the group told Reuters on Monday.

Takeda will hold the shareholder meeting later this year or early next year to approve an issue of new stock to help fund the Shire deal, making it a de facto vote on the deal itself.

The 130 member group formed by ex-Takeda employees holds one percent of the drugmaker's shares, and needs to secure a third of shareholder votes.

It is "working steadily to increase support" for blocking the deal among domestic retail investors and overseas institutional investors who own 25 percent and 35 percent of Takeda shares respectively, the person said on condition of anonymity.

The group includes members of the founding Takeda family, Nikkan Yakugyo reported last month. The family owns about 10 percent of Takeda shares, people familiar with the matter told Reuters.

Last year, the same group attempted to prevent the appointment of outgoing Chairman Yasuchika Hasegawa to an advisory position at the company. Although the proposal was defeated at the company's annual general meeting, it gained 30.5 percent of votes.

The group has a proposal at this month's annual general meeting too, arguing that deals worth more than 1 trillion yen ($9.1 billion) should be put to a shareholder vote.

It does not expect that proposal to pass either, but hopes it will help draw attention to "what an irrational deal" the Shire transaction is, the group member said.

The group argues Takeda is taking on too much financial risk with the acquisition and says Shire's haemophilia franchise is threatened by Roche Holding AG's new haemophilia drug Hemlibra.

Takeda Chief Executive Christophe Weber has expressed confidence shareholders will vote in favour of the deal.

Shares at the drugmaker have fallen more than 20 percent since it first said it was considering bidding for Shire.

($1 = 109.9900 yen)

(Reporting by Sam Nussey; Additional reporting by Ritsuko Shimizu;Editing by Christopher Cushing and Mark Potter)

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 11 2018 | 5:35 PM IST

Next Story